• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Aptar Pharma banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

News

Transpire Bio opens new headquarters and research facility

Transpire Bio, which launched in 2022 to develop inhaled therapeutics for both local and systemic delivery, has officially opened its new headquarters and research facility in Weston, FL, USA. Shortly after launching, the company announced deals with Recipharm for development of 4 inhaled formulations (TRB-1, TRB-2, TRB-3, and TRB-4) and with INTO for 3 additional … [Read more...] about Transpire Bio opens new headquarters and research facility

MannKind gets US patent covering clofazimine inhalation suspension

According to MannKind Corporation, the United States Patent and Trademark Office (USPTO) has issued US patent No. 11,793,808 ("Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods Comprising Them"), which covers the company's MNKD-101 clofazimine inhalation suspension, until 2039. MannKind is developing MNKD-101 … [Read more...] about MannKind gets US patent covering clofazimine inhalation suspension

University of Sydney researchers get $687,000 in FDA funding for development of in vitro testing methods for DPIs

Researchers at the University of Sydney have been awarded $687,000 by the FDA to support a project titled, "Development of a laser-based testing platform for generic dry powder inhaler DPI evaluation and in-silico model validation," the university said. The project is led by Hak-Kim Chan of the Sydney Pharmacy School and Agisilaos Kourmatzis of the School of … [Read more...] about University of Sydney researchers get $687,000 in FDA funding for development of in vitro testing methods for DPIs

FDA accepts AstraZeneca’s sBLA for self-administration of FluMist Quadrivalent intranasal flu vaccine

According to AstraZeneca, the FDA has accepted for review the company's supplemental biologics license application (sBLA) for self-administration of FluMist Quadrivalent nasal spray vaccine against influenza. AstraZeneca says that it expects a PDUFA date in the first quarter of 2024, which would allow for self administration of FluMist for the 2024-25 flu season if … [Read more...] about FDA accepts AstraZeneca’s sBLA for self-administration of FluMist Quadrivalent intranasal flu vaccine

Defender announces that NASA will conduct 2 Phase 2 trials of DPI-386 intranasal scopolamine

Researchers at the United States National Aeronautics and Space Administration (NASA) will lead 2 Phase 2 studies of Defender Pharmaceuticals' DPI-386 scopolamine nasal gel for the prevention of motion sickness induced by sudden changes in gravitoinertial forces (g-transitions) such as those experienced by astronauts. The FDA recently accepted Defender's NDA for … [Read more...] about Defender announces that NASA will conduct 2 Phase 2 trials of DPI-386 intranasal scopolamine

Milestone submits NDA for etripamil nasal spray for the treatment of PVST

Milestone Pharmaceuticals said that it has submitted an NDA for its etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) and that the FDA has conditionally approved the proposed trade name "Cardamyst." The company said that it is continuing preparations for an anticipated commercial launch. According to Milestone, the clinical … [Read more...] about Milestone submits NDA for etripamil nasal spray for the treatment of PVST

Beckley Psytech initiates Phase 2b study of BPL-003 intranasal mebufotenin for treatment resistant depression

Beckley Psytech has announced the initiation of a Phase 2b trial of BPL-003 intranasal synthetic 5-MeO-DMT (mebufotenin) in people with moderate-to-severe treatment resistant depression. In February 2023, the company announced that the FDA approved an IND for the study. A Phase 2a trial of BPL-003 is still underway, Beckley said. The Phase 2b study is expected to … [Read more...] about Beckley Psytech initiates Phase 2b study of BPL-003 intranasal mebufotenin for treatment resistant depression

Qnovia partners with University of Virginia for development of inhaled antimicrobial peptides

Qnovia (formerly Respira Technologies) has announced a partnership with researchers at the University of Virginia (UVA) for the development of two new antimicrobial peptides for delivery via the company's RespiRx vibrating mesh nebulizer technology. The new candidates will be called QN-05, which will be developed for the treatment of pneumonia, and QN-06, for the … [Read more...] about Qnovia partners with University of Virginia for development of inhaled antimicrobial peptides

FDA okays home dosing of Tiziana’s intranasal foralumab for MS patients in expanded access program

According to Tiziana Life Sciences, the FDA is allowing patients with multiple sclerosis who are taking part in an expanded access program through Brigham and Women's Hospital to use intranasal foralumab at home instead of at the hospital. In April 2022, the company announced that the agency had agreed to allow the access program to expand to a total of 10 patients … [Read more...] about FDA okays home dosing of Tiziana’s intranasal foralumab for MS patients in expanded access program

Aculys says it will file NDA based on interim analysis of Japanese Phase 3 trial of NRL-1 (Valtoco) diazepam nasal spray

Aculys Pharma says that it plans to move ahead with submission of a marketing application to Japanese authorities based on interim data showing that a Japanese Phase 3 clinical study of NRL-1 diazepam nasal spray in epilepsy patients aged 6 to 17 met its primary efficacy endpoint. Aculys acquired development and commercialization rights to Neurelis's NRL-1 diazepam … [Read more...] about Aculys says it will file NDA based on interim analysis of Japanese Phase 3 trial of NRL-1 (Valtoco) diazepam nasal spray

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 36
  • Page 37
  • Page 38
  • Page 39
  • Page 40
  • Interim pages omitted …
  • Page 417
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Merxin We Make Inhalers banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews